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Abstract
Purpose of review—We discuss recent advances in the understanding of acquired immunity 
and susceptibility to the two major pediatric enteric viral pathogens, norovirus and rotavirus.
Recent findings—The prominent decline in severe rotavirus gastroenteritis in areas with mature 
rotavirus vaccination programmes has correspondingly unmasked the significant burden of disease 
associated with norovirus gastroenteritis among children. As epidemiologists and vaccinologists 
set their sights on this next vaccine target, we provide an update on norovirus vaccine 
development.
In addition to these developments regarding acquired immunity, refinements to our understanding 
of innate susceptibility to norovirus has advanced. Significant recent advances now describe 
similar immunologic mechanisms in understanding susceptibility for both norovirus and rotavirus, 
involving histo-blood group antigenic associations, which may also prove to be genotype specific.
Summary—This information can potentially be used to tailor both applied and developmental 
efforts to public health interventions against these important pediatric enteric viral pathogens.
Keywords
acquired; FUT2; histo-blood group antigen; immunity; innate; norovirus; rotavirus; vaccine
INTRODUCTION
In some regions with successful rotavirus vaccination programmes, a fundamental shift has 
occurred in the epidemiology of acute gastroenteritis in pediatric populations and norovirus 
has overtaken rotavirus to become the predominant cause of severe gastroenteritis in young 
children. In light of this development, efforts have increasingly been directed toward 
understanding the epidemiology of noroviruses with the ultimate aim of preventing the large 
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burden of disease due to this pathogen. Rapid advancements in molecular and genetic 
technologies have reduced the cost and increased the resolution of previously undetected 
host–pathogen relationships for enteric viral pathogens. This review encompasses the recent 
scientific progress in understanding both immunity and innate susceptibility to these 
important pediatric enteric viral diseases.
NOROVIRUS GASTROENTERITIS DISEASE BURDEN
Before rotavirus vaccines were licensed and recommended by the US Advisory Committee 
on Immunization Practices for routine use in 2006, rotavirus was the leading agent of severe 
pediatric gastroenteritis in US children, causing approximately half of all winter acute 
gastroenteritis hospitalizations in the US. As a result of the marked decline in severe 
rotavirus disease because of vaccination [1▪], noroviruses have now become the leading 
cause of pediatric gastroenteritis in US children [2▪]. An evaluation involving active 
surveillance among children under 5 years old in three US counties showed that laboratory-
confirmed norovirus infection accounted for 21% of gastroenteritis requiring medical 
attention, compared with 12% for rotavirus. Extrapolating from incidence rates in this 
population, nearly 1 million medically attended norovirus infections are estimated to occur 
annually in US children younger than 5 years old, incurring substantial costs upon the US 
healthcare system. In that study, norovirus hospitalization and emergency department rates 
were highest among children between the ages 6 and 23 months. Modeling studies now 
underscore the key role that young children play in norovirus transmission to all age groups 
[3▪], consistent with earlier findings suggesting that contact with a symptomatic child is a 
major determinant in norovirus infection risk.
With increasing use of molecular detection assays, noroviruses are also now recognized to 
be the cause of approximately half of all foodborne disease outbreaks in the US [4]. They 
are a key healthcare-acquired infection, a common cause of travel-associated diarrhea, and 
can blight any close congregation of humans, including long-term care facilities, daycare 
centers, cruise ships, and dormitories [5]. Worldwide, norovirus is associated with 18% of 
acute gastroenteritis cases among children (17% of inpatient cases and 24% of community 
episodes), according to a recent systematic review [6].
NATURAL IMMUNITY TO NOROVIRUS
The understanding of natural immunity to norovirus is far from complete, although it is clear 
that immunity is not permanently sustained and reinfections can occur throughout life. Early 
volunteer studies suggested that protection against rechallenge with the same norovirus 
strain lasted for at least 6 months to 2 years [7,8]. However, both the dose and strain used in 
these challenge studies may not represent typical natural exposures. Estimates from a 
recently published transmission modeling study indicate that the duration of homotypic 
immunity may last longer than originally believed: 4.1 (95% confidence interval [CI] 3.2–
5.1) to 8.7 (95% CI 6.8–11.3) years [3▪]. These models, which were fit to age-specific 
incidence data from England and Wales, also found that children younger than 5 years old 
were more infectious than older children and adults.
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A second feature of norovirus immunity is that protection against one norovirus strain does 
not necessarily provide protection against other strains from the diverse collection of 
noroviruses, which comprise five genogroups and approximately 30 more specific genotypes 
known to infect humans. Rechallenged volunteers have been observed to be susceptible to 
heterologous strains, indicating a lack of cross-protection between genogroup I (GI) and 
genogroup II (GII) noroviruses. Results from a Peruvian birth cohort demonstrated that 
childhood norovirus infection risk is highest during childhood, followed by serial infections 
throughout life [9]. Repeat infections by noroviruses having the same genogroup were 
common in this cohort, but repeat infections from noroviruses having the same specific 
genotype were rarely observed.
Third, the predominant norovirus genotype, GII.4, undergoes a process of epochal evolution, 
whereby every 2–4 years a new variant emerges. Novel GII.4 variants have altered 
antigenicity and they, to some degree, escape immunity in the human population [10]. 
Further, GII.4 is believed to have advantageous characteristics such as being shed in higher 
numbers and perhaps having greater transmissibility than other genotypes [11,12]. The 
continuing evolution of new strains suggests that, as with influenza viruses, continued 
epidemiologic surveillance with periodic reformulations of norovirus vaccines may be 
necessary to keep pace with antigenic changes [13].
Finally, although norovirus is frequently detected in stool samples from patients with 
diarrhea, it is also frequently detected from stools collected from healthy individuals. 
Norovirus detection in the absence of symptoms may be the result of a lengthy period of 
postdisease shedding detectable by PCR or true asymptomatic infection. Overall, detection 
rates in many developed countries are approximately 4–8% among young healthy controls 
[6], but have been observed as high as 30% [14]. Asymptomatic norovirus detections occur 
consistently more frequently among children from lower income countries, however [10], 
perhaps driven by higher rates of infection (and, therefore, increased levels of postinfection 
shedding). This variation complicates the interpretation of diagnostic results and the 
etiologic attribution of gastro-enteritis by comparing detection rates of various pathogens in 
gastroenteritis cases and healthy controls, such as the Global Enterics Multi-Center Study 
(GEMS), the largest systematic assessment for understanding the cause of moderate-to-
severe childhood diarrhea in developing countries [15].
DEVELOPMENT OF A PROSPECTIVE NOROVIRUS VACCINE
As no small animal model or cell culture system is currently able to represent human 
norovirus infection, norovirus vaccine research has been conducted using inactive, 
nonreplicating norovirus capsids that lack the viral genome and are expressed as virus-like 
particles (VLP). These VLPs are morphologically indistinguishable from naturally occurring 
virus capsids and, since they were first engineered over 20 years ago, have been proposed as 
vaccine candidates. In preclinical trials, VLP delivered intra-nasally, intramuscularly and 
orally have all led to measureable serological responses. An adjuvanted intranasal 
formulation was tested in a proof-of-concept efficacy trial, in which participants were 
intranasally administered two doses of adjuvanted norovirus VLP vaccine or placebo 
intranasally 3 weeks apart, then challenged with live virus, homotypic to the vaccine strain 
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[16]. This trial demonstrated greater than four-fold immunoglobulin A antibody rises in 70% 
of vaccinated individuals, who were less likely to become ill (37 vs. 69%, respectively; P = 
0.006) or infected (61 vs. 82%, respectively, P = 0.05) than individuals who received 
placebo. This vaccine has since been further developed as an adjuvanted bivalent 
formulation, including both a GI.1 (Norwalk) and GII.4 (consensus) VLP.
The vaccine was recently assessed in a randomized, double-blind, placebo-controlled trial of 
18–50 year old adults who received two injections of placebo or the norovirus GI.1/GII.4 
bivalent VLP vaccine, and were then challenged with a GII.4 virus [17]. Fewer self-reported 
severe or moderate gastroenteritis symptoms occurred among vaccinated individuals 
compared with placebo recipients. An important outcome of these trials is the identification 
of a promising correlate of protection. Individuals with histo-blood group antigen (HBGA) 
blocking antibodies against norovirus VLPs at titers of 200 or more had a 72% (95% CI 21–
90) reduced risk of norovirus gastroenteritis compared with individuals with titers less than 
200. Further studies will be needed to determine if HBGA-blocking activity can serve as a 
correlate of immunogenicity and protection. If so, this would be an important development 
in the ability to accurately gauge the clinical performance of norovirus vaccines.
Nonetheless, substantial challenges remain to developing a norovirus vaccine that would be 
a useful public health tool. Natural norovirus immunity appears to be of relatively short 
duration with limited cross-protection. Noroviruses are highly diverse viruses so a broadly 
effective vaccine would require bivalency and contain both GI and GII VLPs. With GII.4 
viruses periodically shifting their antigenicity, a vaccine may need to be regularly updated or 
engineered to protect against future strains. Finally, in order to realize the public health 
potential of a norovirus vaccine, it will be critical to demonstrate efficacy in the vulnerable 
groups (e.g., young children and the elderly) who may be the least likely to mount a 
protective vaccine response.
NOROVIRUS INNATE SUSCEPTIBILITY
In addition to acquired immunity from infection or vaccination, a genetic, innate component 
exists to norovirus susceptibility. Revelations first reported in the past decade regarding the 
association between norovirus infection and genetic indicators of HBGA expression have 
been recently refined.
HBGAs are a diverse family of carbohydrates expressed on the mucosal epithelia of the 
respiratory, genitourinary, and digestive tracts, that are recognized as receptors allowing 
norovirus attachment and cellular entry. HBGA production is coded by three gene families 
expressing the ABO (A/B enzymes), secretor (FUT2), and Lewis-type (FUT3) antigens. 
Single-nucleotide polymorphisms can inactivate the expression of these products, breaking a 
link in the norovirus binding and infection process. Recent research indicates that FUT2 
genotype is a major factor determining pediatric norovirus infection risk, particularly with 
the GII.4 norovirus type that predominates worldwide [18].
These genetic characteristics affecting HBGA expression, and thus norovirus infection risk, 
appear to be highly variable by ethnicity. Those without a functional FUT2 secretor gene 
(i.e., nonsecretors) comprise 20–25% of North American/European Caucasian populations, 
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but just 2% of US individuals of Meso-American/Hispanic ancestry. This intimates possibly 
higher natural susceptibility to norovirus infections among Hispanic populations in the 
United States [18]. In South East and East Asians, a different secretor mutation (A385T) is 
common. Twelve percent of Chinese children held the mutation, conferring to them a lower 
risk of GII.4 and GII.3 infections [19]. And, in Vietnam, of the studied children having a 
nonsecretor FUT3 mutation, all were resistant to norovirus variant GII.4 [20▪▪].
It has become increasingly clear that innate human variations in HBGA binding sites on the 
mucosal epithelium affect the risk of norovirus infection. Such findings are relevant to 
understanding variations in norovirus risk within and between populations and may help 
guide the design and interpretation of norovirus vaccine research. Indeed, norovirus vaccine 
challenge studies have typically excluded nonsecretor individuals to ensure susceptibility 
among the challenged individuals. Although this approach maximizes the chance of vaccine 
trials showing a protective effect, it limits the real-world representativeness of the study 
populations.
DOES ROTAVIRUS INNATE SUSCEPTIBILITY EXIST TOO?
Recent studies have reported for the first time evidence of innate susceptibility to rotavirus 
through mechanisms also involving host HBGAs. Laboratory observations reveal that the 
viral protein-8 distal region of human rotavirus spike proteins specifically recognize HBGAs 
[21], illustrating the biological plausibility of this association. Epidemiologic observational 
evidence now supports this molecular finding. Trang et al. [20▪▪], analyzed paired stool-
saliva specimens from Vietnamese children hospitalized with acute gastroenteritis, finding a 
significant relationship between rotavirus gastroenteritis and HBGA status, similar to a 
host–pathogen association with norovirus seen in the same population. This 100% 
correlation between rotavirus infections and secretor status was also reported by Imbert-
Marcille et al. [22▪▪] in a French pediatric sample, and by Payne et al. [23] in an ethnically 
and regionally diverse sample of US pediatric inpatient and emergency department 
admissions for acute gastroenteritis in 2011–2012. Nordgren et al. [24] studied children with 
rotavirus from both Burkina Faso and Nicaragua, finding that rotaviruses having a P[8]-type 
(viral protein, viral protein-4) exclusively infected children having Lewis and secretor 
positive HBGA phenotypes, also suggesting the importance of both FUT2 and FUT3 upon 
rotavirus susceptibility.
The P[8] type is the sole viral protein-4 component of both live, attenuated rotavirus 
vaccines, RotaTeq (Merck and Co., Whitehouse Station, New Jersey, USA) and Rotarix 
(GlaxoSmithKline Biologicals, Rixensart, Belgium), and is the predominant viral protein-4 
type circulating globally. African populations have a high frequency of Lewis-negative 
HBGA phenotypes, therefore, leading Nordgren et al. [24] to surmise that a greater 
proportion of African children are possibly unable to mount an adequate immunologic 
response to the viral protein-4 vaccine component, thereby reducing rotavirus vaccine 
efficacy in clinical trials in African populations. However, this conclusion requires further 
validation and consideration of factors including the broadly heterotypic response 
recognized to be derived from these vaccines in the clinical trial data considered during 
vaccine licensure. These recent HBGA studies, all having relatively small sample sizes, 
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nonetheless provide highly consistent findings that innate susceptibility to rotavirus 
gastroenteritis exists among pediatric populations on four continents, in a mix of 
socioeconomic and environmental conditions.
SUMMARY
Genetic human variations in HBGA expression on the mucosal epithelium strongly affect 
the risk of norovirus infection, and indications of a similar relationship with rotavirus have 
recently been elucidated in diverse populations. This natural resistance to norovirus and 
rotavirus is perhaps associated with ethnicity and specific to particular viral genotypes. As 
stimulating as is the prospect for similar, innate protective mechanisms for both of these 
viral pathogens, many questions await further investigation. Well powered, diverse 
epidemiological assessments are needed, including healthy controls, as are further 
elucidations into the structural mechanisms of HBGA and norovirus/rotavirus interfaces, 
their evolution, and their genotypic differences. This information can potentially be used to 
gain insights into the mechanisms of enteric virus infection and immunity processes, 
facilitate the development of vaccines, and help to target public health interventions, perhaps 
including infection control and vaccine strategies.
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• Progress has occurred in the development and testing of candidate norovirus 
vaccines, including the identification of a possible correlate of protection.
• Innate susceptibility to norovirus, now widely acknowledged to occur through 
host histo-blood group antigen mechanisms, may differ between population 
groups and by norovirus genotype.
• A similar, innate protective mechanism may affect susceptibility to rotavirus.
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